BioSpace News Archive

FSD Pharma Inc. announced that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) has entered into a non-binding memorandum of understanding (“MOU”) with High Tide Ventures Inc.

Two-day conference will bring together senior leaders from across healthcare to explore the provider-payer convergence trends, strategies, and technologies transforming healthcare

The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference

SiteOne Anticipates Filing IND for Lead Candidate by Year-End 2018

Study to evaluate Oral KORSUVA (CR845/difelikefalin) for the Treatment of Pruritus in Stage III-V Chronic Kidney Disease (CKD) Patients

The World Health Organization (WHO) announced that a recent Ebola outbreak in the Democratic Republic of Congo, which killed 8 people since early April, has “largely been contained,” with the last Ebola death reported there June 9th.

The latest advancement of MAGEC® delivers improved rod strength together with internal rod mechanism advancements

Settlement Will Be Paid By Company’s Insurance Carrier

Company provides mid-year update and guidance [19-July-2018] PRINCETON, N.J., July 19, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its Pres

Danaher Corporation announced results for the second quarter 2018.